A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)

Summary

This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer medicines, can still treat the cancer effectively while causing fewer side effects, especially those affecting the eyes. The study will also look at how well the treatment works overall and how safe it is when administered to the participants.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Belantamab mafodotin

  Belantamab mafodotin will be administered.

• Drug
  Dexamethasone

  Dexamethasone will be administered.

• Drug
  Pomalidomide

  Pomalidomide will be administered.

• Drug
  Bortezomib

  Bortezomib will be administered.

• Drug
  Carfilzomib

  Carfilzomib will be administered.

Locations (6)